<DOC>
	<DOCNO>NCT00631475</DOCNO>
	<brief_summary>This Open-label extension study patient Idiopathic Pulmonary Fibrosis complete protocol AC-052-321 / BUILD 3 ( NCT00391443 ) asses long term safety tolerability bosentan patient idiopathic pulmonary fibrosis ( IPF ) .</brief_summary>
	<brief_title>Open Label Extension Study Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Patients complete assessment BUILD 3 ( NCT00391443 ) end study ( EOS ) visit . Signed informed consent prior initiation studyrelated procedure . Women childbearing potential must negative serum pregnancy test use reliable method contraception study treatment 3 month study treatment termination . Any major violation protocol AC052321 / BUILD 3 ( NCT00391443 ) . Pregnancy breastfeed . AST and/or ALT &gt; 3 time upper limit normal range . Any known factor disease might interfere treatment compliance , study conduct interpretation result , drug alcohol dependence psychiatric disease . Known hypersensitivity bosentan excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Actelion</keyword>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>bosentan</keyword>
	<keyword>Tracleer</keyword>
	<keyword>Interstitial Lung Disease</keyword>
	<keyword>BUILD 3 ( NCT00391443 )</keyword>
</DOC>